Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples

Objective. A proportion of RA and SLE patients treated with standard doses of rituximab (RTX) display inefficient B cell deletion and poor clinical responses that can be augmented by delivering higher doses, indicating that standard-dose RTX is a sub-optimal therapy in these patients. This study aim...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Rheumatology (Oxford)
Main Authors: Reddy, Venkat, Klein, Christian, Isenberg, David A., Glennie, Martin J., Cambridge, Geraldine, Cragg, Mark S., Leandro, Maria J.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2017
Teme:
Basic and Translational Science
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5808665/
https://ncbi.nlm.nih.gov/pubmed/28407142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/kex067
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki